Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2019 - 2026)
Phathom Pharmaceuticals (PHAT) reported Amortization of Deferred Charges of $844000.0 for Q1 2026, up 21.26% year-over-year from $696000.0 in Q1 2025, and up 281.51% quarter-over-quarter from -$465000.0 in Q4 2025.
Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 8 years of Amortization of Deferred Charges data on file, last reported at $844000.0 in Q1 2026.
- Amortization of Deferred Charges for Q1 2026 came in at $844000.0, up 21.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 30.99% YoY), and the FY2025 annual result was $3.0 million, up 37.5% from the prior year.
- Amortization of Deferred Charges advanced to $844000.0 in Q1 2026 per PHAT's latest filing, from -$465000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.0 million in Q3 2025 and troughed at -$465000.0 in Q4 2025.
- A 5-year average of $671235.3 and a median of $589000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 247.88% in 2025 and fell as far as 173.93% in 2025.
- A 5-year view of Amortization of Deferred Charges shows it stood at $890000.0 in 2022, then sank by 36.4% to $566000.0 in 2023, then advanced by 11.13% to $629000.0 in 2024, then plunged by 173.93% to -$465000.0 in 2025, then soared by 281.51% to $844000.0 in 2026.
- Business Quant data shows PHAT's Amortization of Deferred Charges at $844000.0 in Q1 2026, -$465000.0 in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 844,000.00 |
| Mar 31, 2026 | 844,000.00 |
| Dec 31, 2025 | -465,000.00 |
| Dec 31, 2025 | -465,000.00 |
| Sep 30, 2025 | 2.05 Mn |
| Sep 30, 2025 | 2.05 Mn |
| Jun 30, 2025 | 734,000.00 |
| Jun 30, 2025 | 734,000.00 |
| Mar 31, 2025 | 696,000.00 |
| Mar 31, 2025 | 696,000.00 |
| Dec 31, 2024 | 629,000.00 |
| Dec 31, 2024 | 629,000.00 |
| Sep 30, 2024 | 589,000.00 |
| Sep 30, 2024 | 589,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 474,000.00 |
| Mar 31, 2024 | 474,000.00 |
| Dec 31, 2023 | 566,000.00 |
| Dec 31, 2023 | 566,000.00 |